Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.49−0.10 (-6.29%)
Close on Nov 12, 2026Market cap $139.64MP/E –Yield –
Innate Pharma total assets
Total assets on the balance sheet at the end of each period.
Innate Pharma's total assets was €34.73M at Jun 30, 2026. For fiscal 2025 it was €62.72M, down 43.5% from the year before. The highest annual figure on record is €451.22M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €62.72M | -43.5% |
| FY2024 | Dec 31, 2024 | €111.06M | -36.6% |
| FY2023 | Dec 31, 2023 | €175.19M | -12.1% |
| FY2022 | Dec 31, 2022 | €199.30M | -25.5% |
| FY2021 | Dec 31, 2021 | €267.50M | -13.0% |
| FY2020 | Dec 31, 2020 | €307.42M | -23.4% |
| FY2019 | Dec 31, 2019 | €401.36M | -11.0% |
| FY2018 | Dec 31, 2018 | €451.22M | +76.9% |
| FY2017 | Dec 31, 2017 | €255.02M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €34.73M | -77.1% |
| Q4 FY2025 | Dec 31, 2025 | €62.72M | -64.2% |
| Q2 FY2025 | Jun 30, 2025 | €92.94M | -53.3% |
| Q4 FY2024 | Dec 31, 2024 | €111.06M | -44.3% |
| Q2 FY2024 | Jun 30, 2024 | €151.50M | -46.0% |
| Q4 FY2023 | Dec 31, 2023 | €175.19M | -34.5% |
| Q2 FY2023 | Jun 30, 2023 | €199.05M | -25.2% |
| Q4 FY2022 | Dec 31, 2022 | €199.30M | -35.2% |
| Q2 FY2022 | Jun 30, 2022 | €280.43M | -30.1% |
| Q4 FY2021 | Dec 31, 2021 | €267.50M | -40.7% |
| Q2 FY2021 | Jun 30, 2021 | €266.22M | +4.4% |
| Q4 FY2020 | Dec 31, 2020 | €307.42M | – |
| Q4 FY2019 | Dec 31, 2019 | €401.36M | – |
| Q4 FY2018 | Dec 31, 2018 | €451.22M | – |
| Q4 FY2017 | Dec 31, 2017 | €255.02M | – |
See a number that looks wrong?